A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Wet Age-related Macular Degeneration - AVANTE Study
Latest Information Update: 14 Jul 2021
At a glance
- Drugs Carotuximab (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms AVANTE
- Sponsors Santen Pharmaceutical
- 09 Mar 2020 Primary endpoint (Mean change from baseline in best corrected visual acuity (BCVA) at Week 24) has not been met, according to a Santen Pharmaceutical media release.
- 09 Mar 2020 Status changed from active, no longer recruiting to discontinued, according to a Santen Pharmaceutical media release.
- 09 Mar 2020 Results presented in the Santen Pharmaceutical Media Release.